Saffron extract linked to mood and sleep gains in menopausal women

A proprietary saffron extract improved mood, self-esteem, and sleep-related outcomes in menopausal and postmenopausal women over 12 weeks, according to results of a randomized, double-blind, placebo-controlled trial published in Frontiers in Nutrition.¹ The findings are clinically notable given the convergence of mood disturbance, sleep disruption, and diminished self-perception that frequently accompanies the menopausal transition—a population for whom evidence-based, low-risk adjunctive options remain limited.

"For this study, we focused on menopausal and post-menopausal women, as this is a period associated with increased vulnerability to mood disturbances, impaired sleep, and accelerated facial ageing," said Adal Mena, R&D Scientist and Product Specialist for Affron, in a news release from the company. "This is the first clinical trial showing that Affron can positively impact three closely connected aspects of well-being: mood, self-esteem, and the daily impact of poor sleep."¹

Trial overview

The trial, led by Adrian Lopresti, PhD, enrolled 86 women aged 50 to 70 years who were experiencing low mood and poor sleep. Participants were randomized to receive either 28 mg of Affron—a standardized saffron extract (≥3.5% Lepticrosalides)—or an identical placebo daily for 12 weeks. Outcomes were assessed using validated self-report instruments at baseline, midpoint, and trial completion, including the Depression, Anxiety and Stress Scale–Depression Subscale (DASS-D), the Rosenberg Self-Esteem Scale, and the PROMIS Sleep Disturbance and Sleep-Related Impairment scales.

The primary efficacy outcome was responder rate on the DASS-D. According to the study, approximately half of women in the Affron group met the prespecified responder threshold, compared with 25.6% in the placebo group—nearly double the placebo response rate. Mood score reductions were reported as 50.7% in the active group vs 31.9% in the placebo group. Improvements in the active group began emerging at the four-week assessment. On the Rosenberg Self-Esteem Scale, the Affron group demonstrated a 10% improvement compared with 4.8% in the placebo group, although the researchers characterized this as an exploratory outcome. The news release did not specify whether between-group differences on secondary outcomes reached statistical significance.

Clinical context

Mood disturbance during the menopausal transition is common and multifactorial, involving fluctuations in estradiol, disrupted sleep architecture, and inflammatory pathway activation.¹ Subthreshold depressive symptoms and sleep complaints affect a substantial proportion of perimenopausal and postmenopausal women and frequently co-occur with diminished self-esteem and body image concerns. Hormone therapy remains a first-line intervention for vasomotor and mood-related symptoms in appropriate candidates, but many women are either ineligible or prefer non-hormonal alternatives, creating a recognized gap in management options.²

Mechanism of action

Affron is standardized to Lepticrosalides, a proprietary complex comprising crocins and safranal, the principal bioactive constituents of Crocus sativus. Preclinical and clinical data suggest saffron's bioactive compounds may modulate serotonin, dopamine, and norepinephrine signaling, upregulate brain-derived neurotrophic factor, and exert antioxidant and anti-inflammatory activity—pathways mechanistically relevant to mood regulation and emotional resilience.³

References

1. Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women's Health Across the Nation (SWAN) over 10 years. Obstet Gynecol Clin North Am. 2011;38(3):609-625. doi:10.1016/j.ogc.2011.05.011
2. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
3. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383. doi:10.3736/jintegrmed2013056